OBJECTIVE: The effects of stimulant medication treatment were investigated in children with mental retardation (MR) and attention-deficit/hyperactivity disorder (ADHD). METHOD: Parent and teacher behavioral ratings and reports of side effects were obtained for children (N = 24, mean age = 10.9 years, SD = 2.4) during aplacebo-controlled, double-blind, crossover treatment trial with 0.15 mg/kg, 0.30 mg/kg, and 0.60 mg/kg b.i.d. dosages of methylphenidate. RESULTS: The most significant improvements occurred at the 0.60 mg/kg methylphenidate dose for teacher ratings of inattention (p =.024), hyperactivity (p <.001), aggression (p <.001), and asocial behavior (p =.009). No significant improvements, relative to placebo, occurred at the 0.15 mg/kg dosage. Of interest, nearly all significant medication-related behavioral improvements were detected by teachers. However, parents were sensitive raters of side effects, noting more sleeping problems and loss of appetite at the 0.60 mg/kg dose compared with placebo. CONCLUSIONS: These results suggest that symptoms of ADHD can be treated successfully in children with ADHD/MR, and consistent with MTA study results, higher doses were most effective. Furthermore, these improvements were not accompanied by increases in symptoms such as staring, social withdrawal, or anxiety.
RCT Entities:
OBJECTIVE: The effects of stimulant medication treatment were investigated in children with mental retardation (MR) and attention-deficit/hyperactivity disorder (ADHD). METHOD: Parent and teacher behavioral ratings and reports of side effects were obtained for children (N = 24, mean age = 10.9 years, SD = 2.4) during a placebo-controlled, double-blind, crossover treatment trial with 0.15 mg/kg, 0.30 mg/kg, and 0.60 mg/kg b.i.d. dosages of methylphenidate. RESULTS: The most significant improvements occurred at the 0.60 mg/kg methylphenidate dose for teacher ratings of inattention (p =.024), hyperactivity (p <.001), aggression (p <.001), and asocial behavior (p =.009). No significant improvements, relative to placebo, occurred at the 0.15 mg/kg dosage. Of interest, nearly all significant medication-related behavioral improvements were detected by teachers. However, parents were sensitive raters of side effects, noting more sleeping problems and loss of appetite at the 0.60 mg/kg dose compared with placebo. CONCLUSIONS: These results suggest that symptoms of ADHD can be treated successfully in children with ADHD/MR, and consistent with MTA study results, higher doses were most effective. Furthermore, these improvements were not accompanied by increases in symptoms such as staring, social withdrawal, or anxiety.
Authors: Stephanie M Sansone; Keith F Widaman; Scott S Hall; Allan L Reiss; Amy Lightbody; Walter E Kaufmann; Elizabeth Berry-Kravis; Ave Lachiewicz; Elaine C Brown; David Hessl Journal: J Autism Dev Disord Date: 2012-07
Authors: Patricia A Sirois; Lisa Aaron; Grace Montepiedra; Deborah A Pearson; Suad Kapetanovic; Paige L Williams; Patricia A Garvie; Molly L Nozyce; Kathleen Malee; Sharon L Nichols; Betsy L Kammerer; Wendy G Mitchell; Mark Mintz; James M Oleske Journal: Pediatr Infect Dis J Date: 2016-01 Impact factor: 2.129
Authors: Katherine Nickels; Slavica K Katusic; Robert C Colligan; Amy L Weaver; Robert G Voigt; William J Barbaresi Journal: J Dev Behav Pediatr Date: 2008-04 Impact factor: 2.225
Authors: Patricia A Sirois; Grace Montepiedra; Suad Kapetanovic; Paige L Williams; Deborah A Pearson; Kathleen Malee; Patricia A Garvie; Betsy L Kammerer; Sharon L Nichols; Molly L Nozyce; Mark Mintz; Wendy G Mitchell; James M Oleske Journal: J Dev Behav Pediatr Date: 2009-10 Impact factor: 2.225